Sandoz

Sandoz’s improvements are worth betting on

08/05/24 -"Sandoz is moving ahead well with two crucial aspects of its medium-term sales and profitability goals: 1/ a strong performance from Biosimilars and 2/ a turnaround of its US operations, which had ..."

PDF page sample
Pages
53
Language
English
Published on
08/05/24
Download
You may also be interested by these reports :
20/05/24
BioNTech (Buy, Germany) is a beacon among the much-battered German biotechnology cohort. Founded with venture capital in 2008, the company sits on a ...
17/05/24
We have incorporated higher royalty payments in 2024 related to the sale of the generic version of sodium oxybate (medicine to treat symptoms of ...
15/05/24
The Q1 results surpassed the consensus estimates, driven by a sustained strong performance from the strategic products. The management nonetheless ...
15/05/24
Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO